Roberto Ortiz

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations

Medicine, Oncology, Pharmacology +14

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet, Judith Feinberg, Jan van Lunzen et al. · The Lancet · 2014 · 501 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +12

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou et al. · AIDS · 2008 · 383 citations

Medicine, Pharmacology, Pharmacotherapy +17

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17